GW3965 HClLXR agonist, selective and orally active CAS# 405911-17-3 |
- ARP 100
Catalog No.:BCC2370
CAS No.:704888-90-4
- Alvelestat
Catalog No.:BCC4058
CAS No.:848141-11-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 405911-17-3 | SDF | Download SDF |
PubChem ID | 16078973 | Appearance | Powder |
Formula | C33H32Cl2F3NO3 | M.Wt | 618.51 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 125 mg/mL (202.10 mM) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]propoxy]phenyl]acetic acid;hydrochloride | ||
SMILES | C1=CC=C(C=C1)C(CN(CCCOC2=CC=CC(=C2)CC(=O)O)CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=CC=C4.Cl | ||
Standard InChIKey | NMPUWJFHNOUNQU-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C33H31ClF3NO3.ClH/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26;/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective, orally active non-steroidal agonist for the liver X receptor (LXR). In cell-based reporter gene assays, acts as a full agonist of hLXRα and hLXRβ (EC50 values are 190 and 30 nM respectively). Reduces angiotensin II-mediated increases in blood pressure; up-regulates ABCA1 gene expression and raises circulating HDL levels. Displays potent antiatherogenic activity in mouse models of atherosclerosis. |
GW3965 HCl Dilution Calculator
GW3965 HCl Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.6168 mL | 8.0839 mL | 16.1679 mL | 32.3358 mL | 40.4197 mL |
5 mM | 0.3234 mL | 1.6168 mL | 3.2336 mL | 6.4672 mL | 8.0839 mL |
10 mM | 0.1617 mL | 0.8084 mL | 1.6168 mL | 3.2336 mL | 4.042 mL |
50 mM | 0.0323 mL | 0.1617 mL | 0.3234 mL | 0.6467 mL | 0.8084 mL |
100 mM | 0.0162 mL | 0.0808 mL | 0.1617 mL | 0.3234 mL | 0.4042 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GW3965 HCl is a selective, orally active non-steroidal agonist for the liver X receptor (LXR) [1].
Nuclear receptors LXRα and LXRβ have an important role in control of cholesterol and fatty acid metabolism in multiple cell types. Activation of these receptors promotes bile acid synthesis in liver, inhibits intestinal cholesterol absorption and stimulates cholesterol efflux in macrophages, which will then reduce atherosclerotic risk [2].
In a cell-free ligand-sensing assay, GW3965 recruits the steroid receptor coactivator 1 to human LXRR with an EC50 of 125 nM. In cell-based reporter gene assays, GW3965 plays as a full agonist on hLXRα and hLXRβ with EC50 of 190 and 30 nM, respectively [1].
Treatment C57BL/6 mice with 10 mg/kg GW3965 HCl orally, GW3965 HCl increased the plasma concentrations of HDL cholesterol by 30% and enhanced the expression of the reverse cholesterol transporter ABCA1 in the small intestine and peripheral macrophages [1]. In male Sprague–Dawley rats, GW3965 decreased Ang II-mediated vasopressor responses and reduced ATR gene expression, which suggested GW3965 can affect vascular reactivity [3].
References:
[1]. Collins JL, Fivush AM, Watson MA, et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem, 2002, 45(10): 1963-1966.
[2]. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A, 2002, 99(11): 7604-7609.
[3]. Leik CE, Carson NL, Hennan JK, et al. GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br J Pharmacol, 2007, 151(4): 450-456.
- GW3965
Catalog No.:BCC1612
CAS No.:405911-09-3
- SB590885
Catalog No.:BCC4392
CAS No.:405554-55-4
- Cyclapolin 9
Catalog No.:BCC7571
CAS No.:40533-25-3
- Dadahol A
Catalog No.:BCN5457
CAS No.:405281-76-7
- NFPS
Catalog No.:BCC7484
CAS No.:405225-21-0
- Dovitinib (TKI-258, CHIR-258)
Catalog No.:BCC1169
CAS No.:405169-16-6
- CHIR-124
Catalog No.:BCC3750
CAS No.:405168-58-3
- Besifloxacin HCl
Catalog No.:BCC4764
CAS No.:405165-61-9
- Drechslerine D
Catalog No.:BCN7502
CAS No.:405157-88-2
- Drechslerine A
Catalog No.:BCN7561
CAS No.:405157-84-8
- Salubrinal
Catalog No.:BCC4843
CAS No.:405060-95-9
- 4'-Demethylpodophyllotoxin
Catalog No.:BCN2625
CAS No.:40505-27-9
- C34
Catalog No.:BCC5603
CAS No.:40592-88-9
- Cirazoline hydrochloride
Catalog No.:BCC6833
CAS No.:40600-13-3
- DMT-Cl
Catalog No.:BCC2799
CAS No.:40615-36-9
- DMT-T
Catalog No.:BCC2843
CAS No.:40615-39-2
- DSP-4
Catalog No.:BCC7527
CAS No.:40616-75-9
- ACHP
Catalog No.:BCC6223
CAS No.:406208-42-2
- IKK-2 inhibitor VIII
Catalog No.:BCC1642
CAS No.:406209-26-5
- Cornoside
Catalog No.:BCN7575
CAS No.:40661-45-8
- Taxifolin 3-O-beta-D-xylopyranoside
Catalog No.:BCN5458
CAS No.:40672-47-7
- O-Phospho-L-serine
Catalog No.:BCC6578
CAS No.:407-41-0
- Actinine
Catalog No.:BCN1744
CAS No.:407-64-7
- (-)-Bicuculline methiodide
Catalog No.:BCC7387
CAS No.:40709-69-1
GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats.[Pubmed:17420776]
Br J Pharmacol. 2007 Jun;151(4):450-6.
BACKGROUND AND PURPOSE: Liver X receptors (LXRs) activate genes that regulate lipid and cholesterol metabolism. LXR agonists were shown recently to also increase murine renin gene expression in vivo. To further examine a link between lipid metabolism, the renin-angiotensin-aldosterone-system and blood pressure regulation, we investigated the effect of a LXR agonist (GW3965) on angiotensin II (Ang II)-mediated vasoreactivity and vascular angiotensin II receptor (ATR) gene expression. EXPERIMENTAL APPROACH: Arterial blood pressure (BP) was measured during Ang II infusions (1.5 min duration; 0.001-3 microg kg(-1)) in pentobarbital-anesthetized male Sprague-Dawley rats (n = 6-9) after oral administration of GW3965 (10 mg kg(-1), q.d.) or vehicle for 7 - 15 days. Mesenteric arteries and plasma were collected to analyze ATR gene expression and to measure plasma renin activity (PRA) and lipid profile, respectively. KEY RESULTS: Basal mean arterial pressure (MAP) was similar between groups. GW3965 dosing blunted the vasopressor effect of Ang II, which was significantly different with the 0.3 and 3 microg kg(-1) doses. No difference in heart rate, PRA or lipid profile was observed between groups. A time-course indicated that ATR type 1 and 2 gene expression of GW3965-treated vs. vehicle-treated rats decreased by 50%, reaching significance for ATR type 2, but not for ATR type 1, at time-points coinciding with BP measurements. CONCLUSIONS AND IMPLICATIONS: GW3965 decreased Ang II-mediated vasopressor responses coincident with a trend toward reduced ATR gene expression, suggesting that LXR agonists could affect vascular reactivity.
Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines.[Pubmed:11985463]
J Med Chem. 2002 May 9;45(10):1963-6.
A potent, selective, orally active LXR agonist was identified from focused libraries of tertiary amines. GW3965 (12) recruits the steroid receptor coactivator 1 to human LXRalpha in a cell-free ligand-sensing assay with an EC(50) of 125 nM and profiles as a full agonist on hLXRalpha and hLXRbeta in cell-based reporter gene assays with EC(50)'s of 190 and 30 nM, respectively. After oral dosing at 10 mg/kg to C57BL/6 mice, 12 increased expression of the reverse cholesterol transporter ABCA1 in the small intestine and peripheral macrophages and increased the plasma concentrations of HDL cholesterol by 30%. 12 will be a valuable chemical tool to investigate the role of LXR in the regulation of reverse cholesterol transport and lipid metabolism.